A Big Moment for Biotech in the US

“Biomanufacturing” by MiraCosta Community College is marked with Public Domain Mark 1.0.

$US 2B to Biotechnology and Biomanufacturing  Innovation

The work week beginning September 12th, 2022 has ushered in a new era of excitement and optimism for the biotechnology and biomanufacturing innovation industries in the U.S.  More than $US 2B is to be dedicated to an initiative launched by executive order of the Biden administration. The national mission, called “Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe and Secure Bioeconomy”, is the culmination of more than ten years of policy development work.

A summit was held on Wednesday, September 14th to launch the initiative, define the goals, and outline how the funding will flow. U.S. National Security Advisor Mr. Jake Sullivan, Director of the National Economic Council Brian Deese and Dr. Alondra Nelson, Director of the White House Office of Science and Technology (OSTP) co-led the summit.

In brief, the top-level goals and delivery agents of the national mission are as follows:

  • Strengthen supply chains for essential medications (active pharmaceutical ingredients, antibiotics, starting materials) with a US $40m investment led by the Department of Health and Human Services.
  • Expand domestic biomanufacturing with a US $1b investment by the Department of Defense.
  • Continue the launch of Regional Innovation Engines across the U.S., with a competition launched by the National Science Foundation.
  • Reduce greenhouse gas emissions through 1) the conversion of biomass to fuels and chemicals, or improved production and recycling of biobased plastics; and 2) scale-up of pilot biorefineries producing renewable chemicals and fuels for transportation, industry and agriculture, with a $US 160m by the Department of Energy.
  • Train next-generation biotechnologists under a new entrepreneurship bootcamp launched by the National Institutes of Health called I-Corps.
  • Support advanced biomanufacturing by enhancing and improving the regulatory machinery at the Federal Drug Administration, including bolstering science and technology (S&T) personnel, equipment, facilities and systems, and engaging more effectively with industry.
  • Measurement technologies, standards and data applicable to the bioeconomy are to be improved and devised by the National Institute of Standards and Technology (NIST) with an investment in NIST of US$ 14m by the Department of Commerce.

Visit the White House FACT SHEET here, or  GEN news for more details. Should you wish even more information, such as briefing notes on a particular topic or on-line presentations, we can help you save time. Let us know your needs and we will supply a quote. You can contact us here.

 

Sep 15th, 2022

Comments are closed.